Repost: Great thoughts from BluMarlin...
In order for Tapimmune to continue as an ongoing entity the largest shareholders had to agree in principle to the restructuring, and then have enough confidence to continue to fund the company through the process.
I also am pondering the effect that another R/S would do to those that believed and allowed the company to continue or simply walk away. I think that it would be very hard for the company to initiate another R/S without overwhelming approval from those shareholders. Which I believe would be very tough.
Point 2: Tapimmune's share price is ludicrous at these levels given their depth of science and imminent catalyst's, without question it should be between $1 and $2 at this point in development.
I have looked at length at most of the Bio's in this space, at fundamentally the same juncture as TPIV that don't have nearly the potential [multi billion dollar markets] I usually go back 5 years and most if not all have within that timeframe seen share prices ranging from $2 to $7. Many have dropped back down, but have seen those lofty valuations and share price.
It is my opinion that by year end we should be in 2 maybe 3 trials, TNBC, Ovarian [the Cancer that took my mother] and the HER2Nue. If any indications of other stocks in this space we will see share prices over minimum $2.
Nasdaq listing has various ways to up list and Tapimmune is putting in place many of the requirements to that end, so far they are right on track to executing what is needed.
I don't know if by year end they can manage to up list, but will be well on their way, and if not by then look for early 2016. But upon initiation of our Phase 11 trials we should garner much attention and think it will be very hard for large institutions to not be buyers. Float is tight and share should move up accordingly.
I still believe that in 2016 with 3 trials ongoing that there is a very good chance, that we will at the very least have a great partnership. But my thoughts are still that we will be bought out at levels no lower than $10.
We must remember that until they finalized the IND of the Folate Receptor science, Tapimmune really had little to no assets [TAP, and Polystart] but still in pre-clinical.
Now they really have a viable company and on the initiation[licencing] of the HER2Nue should be very attractive.
I have spoken with principles of the company and can only say that they seem to be of the same mind.
The market will not be able to ignore the low cost to produce TPIV, it's limited Toxicity not to mention they seem to have the best science to date. A science that can be used in combination with most other applications in development at this time.
Once again who can dispute the findings of Keith Knutson, Edith Perez, Glynn, John who have seen all the data and are still on board.
I also think they will get the grant that they have applied for which will bolster our bottom line.
I am more bullish than ever, for Tapimmune with the licencing of the Folate science [HER2Nue forthcoming] has positioned itself to become a company that may change Cancer as we know it.
GLTA
